Gastroenteropancreatic neuroendocrine tumour disease

9 trials 3 recruiting MedDRA PT
9 Registered trials
3 Recruiting
7 Unique sponsors
14 Unique IMPs
7 Commercial trials
Drug classes (ATC)
V Various (ATC V) 6
H Endocrinology (ATC H) 3
L Oncology (ATC L) 2
— ATC code not specified 2
Mechanism of action (INN-stem analysis)
Unknown / small molecule 6 substances
Radiopharmaceutical 2 substances
Monoclonal antibody (immune) 2 substances
mTOR inhibitor 1 substance
Antimetabolite 1 substance
Supportive / rescue 1 substance
Platinum compound 1 substance
Phase III: 6 Phase II: 2 Phase IV: 1

Filter these 9 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 9 trials

Phase III

6 trials
  • Advanced Accelerator Applications Commercial
    L-LYSINE HYDROCHLORIDE, L-ARGININE HYDROCHLORIDE; LUTETIUM (177LU) OXODOTREOTIDE; OCTREOTIDE
    2023-507443-10-00 5 countries 2019 n=90 Orphan
    Ended
  • Camurus AB Commercial
    LANREOTIDE; OCTREOTIDE; OCTREOTIDE HYDROCHLORIDE
    2023-508723-12-00 8 countries 2021 n=234
    Ended
  • ITM Solucin GmbH Commercial
    EVEROLIMUS; L-LYSINE HYDROCHLORIDE, L-ARGININE HYDROCHLORIDE; LUTETIUM (177LU) EDOTREOTIDE
    2023-510444-21-00 9 countries 2017 n=268 Orphan
    Ended
  • ITM Solucin GmbH Commercial
    L-LYSINE HYDROCHLORIDE, L-ARGININE HYDROCHLORIDE; LUTETIUM (177LU) EDOTREOTIDE
    2024-510812-64-00 5 countries 2021 n=153 Orphan
    Ended
  • Novartis Pharma AG Commercial
    ARGININE HYDROCHLORIDE, LYSINE HYDROCHLORIDE; LUTETIUM (177LU) OXODOTREOTIDE; OCTREOTIDE
    2024-518325-15-00 7 countries 2025 n=100 Orphan
    Recruiting
  • Rayzebio Inc. Commercial
    ACTINIUM (AC 225) OXODOTREOTIDE
    2023-509334-19-00 4 countries 2024 n=78
    Recruiting

Phase II

2 trials
  • Advanced Accelerator Applications Commercial
    L-LYSINE HYDROCHLORIDE, L-ARGININE HYDROCHLORIDE; LUTETIUM (177LU) OXODOTREOTIDE
    2023-507444-37-00 3 countries 2021 n=5 Orphan
    Ended
  • Hospices Civils De Lyon Academic
    DOMVANALIMAB; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; ZIMBERELIMAB
    2024-517254-99-00 1 country 2025 n=186
    Halted

Phase IV

1 trial
  • Antwerp University Hospital Academic
    IMP not specified
    2022-502703-30-00 2 countries 2023 n=270
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Advanced Accelerator Applications Commercial 2 Phase II, Phase III 0
ITM Solucin GmbH Commercial 2 Phase III 0
Camurus AB Commercial 1 Phase III 0
Novartis Pharma AG Commercial 1 Phase III 1
Rayzebio Inc. Commercial 1 Phase III 1
Hospices Civils De Lyon Academic 1 Phase II 0
Antwerp University Hospital Academic 1 Phase IV 1
New trials by year
2019
1
2021
3
2023
1
2024
1
2025
2
← All indication landscapes